LAL, kinetic chromogenic, recombinant factor C: three ways to the same figure

The unit of account is the endotoxin unit, defined against an international reference standard rather than a mass, because different lipopolysaccharide preparations differ substantially in potency. One endotoxin unit corresponds to roughly a tenth of a nanogram of the reference material. The limit for a parenteral product other than an intrathecal one is conventionally derived from a threshold pyrogenic dose of five endotoxin units per kilogram of body weight per hour, divided by the maximum dose administered in that period. The arithmetic takes one line, and the Journal has yet to see it printed on a research-peptide certificate.

Three method families, and what each returns

The gel-clot method is the oldest and simplest: lysate is combined with the sample, incubated, and the tube inverted. A firm clot that does not slip is a positive. It is a limit test, and by testing serial dilutions it becomes semi-quantitative. Its virtues are robustness and independence from instrumentation; its limitation is resolution.

Turbidimetric methods read the increasing turbidity produced by clotting protein formation, either as an endpoint at fixed time or kinetically as the time to reach a defined turbidity. Chromogenic methods substitute a synthetic peptide substrate that releases a chromophore when cleaved by the activated enzyme, and read absorbance. The kinetic chromogenic variant — measuring the time to a defined absorbance change against a standard curve — is the method of record for most modern release testing, offering quantitation across several orders of magnitude from a small sample volume.

All three are compendial, all three require a demonstration that the sample matrix neither inhibits nor enhances the reaction, and all three are calibrated against an international reference endotoxin rather than against a mass. A result reported without the method and without the inhibition-enhancement result is, once again, a number without a procedure.¹

The endotoxin limit, calculated

The limit is derived, not looked up. For a parenteral product other than an intrathecal one, the threshold pyrogenic dose is taken as five endotoxin units per kilogram of body weight per hour. The endotoxin limit for the product is that figure divided by the maximum dose per kilogram administered within an hour. For an intrathecal route the threshold falls to 0.2 endotoxin units per kilogram, a twenty-five-fold reduction that reflects the absence of the systemic buffering the bloodstream provides.

Work it for a concrete case. A seventy-kilogram subject has an hourly allowance of three hundred and fifty endotoxin units. A vial nominally containing five milligrams of peptide, reconstituted to two millilitres, from which a fifth of a millilitre is drawn, delivers a tenth of the vial contents. If the whole vial carried three hundred and fifty endotoxin units, that draw would deliver thirty-five — a tenth of the allowance. The limit expressed per milligram of peptide is what a certificate should carry, because it is the only form of the number that survives a change in reconstitution volume.

None of the arithmetic is difficult. What is missing from this trade is not the calculation but the measured numerator.²

Low endotoxin recovery, and the clean result that is wrong

The most uncomfortable finding in endotoxin testing over the past fifteen years is that certain formulation matrices cause added endotoxin to become undetectable over time. Spike a known quantity of reference endotoxin into a solution containing a non-ionic surfactant and a chelating buffer, hold it, and the recoverable endotoxin declines — sometimes to a small fraction of what was added — while nothing has been removed. The lipopolysaccharide aggregate state has changed, and the assay cannot see what it cannot bind.

The phenomenon is called low endotoxin recovery, and it matters because the combination of polysorbate with citrate or phosphate is extremely common in peptide and protein formulations. A hold-time study — spiking the actual product matrix and measuring recovery across the intended sample storage interval — is the standard mitigation, and it is now expected as part of method suitability for products in that formulation space.

The implication for a reader is narrow but worth stating. A negative endotoxin result on a surfactant-containing formulation, reported without a hold-time recovery study, is weaker evidence than it appears. A negative result on a reconstituted lyophilised peptide in plain water for injection, tested promptly, is considerably stronger.³

Depyrogenation, and the step that gets skipped

Because endotoxin survives sterilisation, glass components require a separate treatment. The standard is dry heat: a tunnel or oven cycle at two hundred and fifty degrees or above, validated to achieve at least a three-log reduction in a deliberately applied endotoxin challenge. Vials emerging from a qualified depyrogenation tunnel are both sterile and pyrogen-free, and they remain so only if the subsequent handling maintains it.

Elastomeric closures cannot take that treatment and are instead washed, siliconised and steam-sterilised by a validated cycle, with endotoxin control achieved by the washing step and specified as a limit per stopper. Water for injection is controlled at source, with a compendial endotoxin specification, and a water system is the commonest origin of a pyrogen problem in an otherwise competent facility.

Depyrogenation is also, in the Journal’s experience of asking, the step most frequently absent from descriptions of small fill operations. Autoclaved vials are sterile. Autoclaved vials are not depyrogenated, and an operation that describes its glass preparation solely in terms of autoclaving has told you something specific about what it has not done. We put this point to eleven correspondents; two said their glass is depyrogenated by dry heat with a validated cycle, and one asked us what depyrogenation was, which we took as a straight answer and a useful one.

What we submitted, and what came back

Between the second and fourth quarters the Journal purchased fourteen vials of lyophilised research peptide from nine suppliers, at catalogue prices, through ordinary channels and without identifying ourselves. Each was photographed sealed, logged, and stored at two to eight degrees on arrival. Twelve were submitted to a contract laboratory accredited to the general competence standard for testing laboratories for bacterial endotoxin determination by kinetic chromogenic assay, with method suitability established for each matrix. Two were submitted for a compendial sterility test by membrane filtration, which destroyed both.

We disclose the following limitations without being asked. Fourteen vials from nine suppliers is not a survey. Single determinations carry the uncertainty of single determinations. A negative sterility result on one vial says nothing about the batch it came from, for exactly the statistical reasons set out above. And a vial that has crossed a border in a padded envelope has a thermal and mechanical history we cannot reconstruct.

What the exercise establishes is narrower than a survey and, we think, worth publishing: that the tests exist, that they are commercially available to a private purchaser at a known price, that the numbers they return are interpretable against a calculable limit, and that nothing prevented any of the nine suppliers from commissioning them first.⁴

We will keep asking the five questions, printing the answers, and recording the refusals as refusals. Two companies changed their certificates after the first round of this correspondence, which is a small result for a year of letters and rather better than none. Documents to letters@compoundjournal.com; disputes about anything above to standards@compoundjournal.com.